These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38567654)

  • 1. MC4R variants modulate α-MSH and setmelanotide induced cellular signaling at multiple levels.
    Rodríguez Rondón AV; Welling MS; van den Akker ELT; van Rossum EFC; Boon EMJ; van Haelst MM; Delhanty PJD; Visser JA
    J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38567654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
    Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
    Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
    Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.
    Reininghaus N; Paisdzior S; Höpfner F; Jyrch S; Cetindag C; Scheerer P; Kühnen P; Biebermann H
    Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Characterization of Novel
    Mohammed I; Selvaraj S; Ahmed WS; Al-Barazenji T; Hammad AS; Dauleh H; Saraiva LR; Al-Shafai M; Hussain K
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of melanocortin-4 receptor signaling: agonist-mediated desensitization and internalization.
    Shinyama H; Masuzaki H; Fang H; Flier JS
    Endocrinology; 2003 Apr; 144(4):1301-14. PubMed ID: 12639913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
    Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Loss of Function Melanocortin-4-Receptor Mutation (MC4R-F313Sfs*29) in Morbid Obesity.
    Trevellin E; Granzotto M; Host C; Grisan F; De Stefani D; Grinzato A; Lefkimmiatis K; Pagano C; Rizzuto R; Vettor R
    J Clin Endocrinol Metab; 2021 Mar; 106(3):736-749. PubMed ID: 33247923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation.
    Brouwers B; de Oliveira EM; Marti-Solano M; Monteiro FBF; Laurin SA; Keogh JM; Henning E; Bounds R; Daly CA; Houston S; Ayinampudi V; Wasiluk N; Clarke D; Plouffe B; Bouvier M; Babu MM; Farooqi IS; Mokrosiński J
    Cell Rep; 2021 Mar; 34(12):108862. PubMed ID: 33761344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
    Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
    Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide.
    Heyder NA; Kleinau G; Speck D; Schmidt A; Paisdzior S; Szczepek M; Bauer B; Koch A; Gallandi M; Kwiatkowski D; Bürger J; Mielke T; Beck-Sickinger AG; Hildebrand PW; Spahn CMT; Hilger D; Schacherl M; Biebermann H; Hilal T; Kühnen P; Kobilka BK; Scheerer P
    Cell Res; 2021 Nov; 31(11):1176-1189. PubMed ID: 34561620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity.
    Lotta LA; Mokrosiński J; Mendes de Oliveira E; Li C; Sharp SJ; Luan J; Brouwers B; Ayinampudi V; Bowker N; Kerrison N; Kaimakis V; Hoult D; Stewart ID; Wheeler E; Day FR; Perry JRB; Langenberg C; Wareham NJ; Farooqi IS
    Cell; 2019 Apr; 177(3):597-607.e9. PubMed ID: 31002796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
    Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
    Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin G modulation of the melanocortin 4 receptor signaling in obesity and eating disorders.
    Lucas N; Legrand R; Bôle-Feysot C; Breton J; Coëffier M; Akkermann K; Järv A; Harro J; Déchelotte P; Fetissov SO
    Transl Psychiatry; 2019 Feb; 9(1):87. PubMed ID: 30755592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Signaling Profiles of MC4R Mutations with Three Different Ligands.
    Paisdzior S; Dimitriou IM; Schöpe PC; Annibale P; Scheerer P; Krude H; Lohse MJ; Biebermann H; Kühnen P
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
    Falls BA; Zhang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype.
    Kamermans A; Verhoeven T; van Het Hof B; Koning JJ; Borghuis L; Witte M; van Horssen J; de Vries HE; Rijnsburger M
    Front Immunol; 2019; 10():2312. PubMed ID: 31636637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
    Lazareva J; Brady SM; Yanovski JA
    Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects.
    Tao YX; Segaloff DL
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5632-8. PubMed ID: 16030156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.